Health & Biotech
Incannex Healthcare Limited (IHL.ASX) is a clinical stage pharmaceutical development company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of Generalised Anxiety Disorder (GAD), Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury (TBI)/Concussion, rheumatoid arthritis, inflammatory bowel disease and inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis).
FDA registration and marketing approval, subject to ongoing clinical success, is being pursued for each product and therapy under development.
Each indication represents major global markets and currently have either no, or limited, existing registered pharmacotherapy (drug) treatments available to the public, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.
Incannex has a strong patent filing strategy as it develops its products and therapies in conjunction with its medical and scientific advisory board and its collaborative partners, including Monash University and The Alfred Hospital.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Incannex achieves major milestone as anti-inflammatory drug well tolerated in Phase-1 trial
Health & Biotech
Could these Aussie psychedelics stocks carve a slice out of a ‘potential $63 billion’ global market?
News
ASX Quarterly Wrap: Here are the stocks to watch today as we enter the crucial quarterly reporting season
News
Closing Bell: Fridayitis as ASX slumps 0.35%, gold still on topsy-turvy ride
Health & Biotech
Weed Week: 420 reminds us that cannabis stocks may be down, but by no means out
Health & Biotech
Incannex makes key appointment to fast-track commercialisation of key products for addiction and skin diseases
News
Market Highlights: ASX to rise after Wall Street rally, EU opens taskforce on ChatGPT, and 5 ASX small caps to watch today
News
Banking on pot: Minus one global investment house, Switzerland moves to legalise cannabis
Health & Biotech
Incannex to open psychedelic clinic’s business with leading Australian experts
Health & Biotech
ASX Health Stocks: High fives as Telix gets expanded FDA approval, Prescient’s PTX-100 returns good results
Health & Biotech
Incannex’s interim data predicts a statistically significant benefit for psilocybin therapy over placebo when treating anxiety, FDA IND application now in sight
News
CLOSING BELL: It’s a scary end to the week as ASX suffers worst hit in five months
Health & Biotech
Incannex commences manufacture of psilocybin for trials and commercial applications
News
Market Highlights: Crypto bank Silvergate on the brink, and 5 ASX small caps to watch today
News
CLOSING BELL: Aussies find a cost of living crisis fix, by stealing everything not nailed down
Health & Biotech
Incannex begins major Phase-2 trial for CBD-enhanced combination drug for rheumatoid arthritis
Experts